FATE vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jan 20, 2026
FATE
60.0
AI Score
VS
MRNA Wins
MRNA
60.3
AI Score
Investment Advisor Scores
MRNA
60score
Recommendation
BUY
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | FATE | MRNA | Winner |
|---|---|---|---|
| Revenue | 5.28M | 1.27B | MRNA |
| Net Income | -103.94M | -2.00B | FATE |
| Net Margin | -1969.7% | -157.7% | MRNA |
| Operating Income | -112.98M | -2.22B | FATE |
| ROE | -44.4% | -21.4% | MRNA |
| ROA | -30.2% | -16.4% | MRNA |
| Total Assets | 343.67M | 12.13B | MRNA |
| Cash | 40.62M | 1.13B | MRNA |
| Current Ratio | 7.87 | 3.93 | FATE |
| Free Cash Flow | -87.53M | -2.96B | FATE |
Frequently Asked Questions
Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.